Novel preparation process of trelagliptin succinate

A one-pot technology of troxagliptin succinate, applied in the field of drug synthesis, can solve problems such as labor costs, waste water defects, and three waste treatment costs

Inactive Publication Date: 2021-04-23
山东永丞制药有限公司
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0012] 1) The cost of starting materials and reagents; 2) The cost of equipment, safety, and environmental protection; 3) The cost of three wastes treatment; 4) Labor cost
[0013] After a comprehensive analysis, 2-4 are the key points of cost, and one of the keys is the problem of the three wastes: the generation of the three wastes directly leads to the treatment cost of the three wastes, the cost of safety and environmental protection, and the cost of labor
In the traditional synthesis method of troxagliptin succinate, during the reaction process, it is necessary to add an organic base as an acid-binding agent, and a large amount of salt is produced by acid-base neutralization, and the waste water has obvious defects;

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel preparation process of trelagliptin succinate
  • Novel preparation process of trelagliptin succinate
  • Novel preparation process of trelagliptin succinate

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0040] Step 1: Preparation of 2-[(6-chloro-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl)methyl]-4-fluorobenzonitrile

[0041] Add 100 g of 3-methyl-6-chlorouracil, 140 g of 2-cyano-5-fluorobenzyl bromide (1.05 equivalents), 800 ml of toluene, and 38.4 g of potassium hydroxide (1.1 equivalents) into the reaction flask. The reaction was stirred at 40-50° C., detected by TLC, and the reaction was complete in 3 hours, which was directly used for the next reaction.

[0042] Step 2: Preparation of Boc-Trexagliptin

[0043] Add 113.2 g of (R)-3-Boc-aminopiperidine dihydrochloride (1.05 equivalents) to the reaction flask of the first step above, stir and react at 40-50° C., detect by TLC, and complete the reaction in 2 hours. After filtering, the solvent of the filtrate was evaporated to dryness to obtain Boc-trexagliptin.

[0044] Step 3: Preparation of Trexagliptin

[0045] Add the above-mentioned Boc-trexagliptin to 400 ml of trifluoroacetic acid, stir and react at 30-40° C....

Embodiment 2

[0049] Different from Example 1: the first and second reaction solvents are N-dimethylformamide (DMF), the total yield of the four-step reaction is 75.2%, and the HPLC purity is 99.73%.

Embodiment 3

[0051]Different from Example 1: the first and second reaction solvents are N-methylpyrrolidone (NMP), the total yield of the four-step reaction is 75.5%, and the HPLC purity is 99.76%.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a novel preparation process of trelagliptin succinate. According to the method, 3-methyl-6-chlorouracil is taken as a starting raw material, toluene, DMF or NMP is taken as a solvent to react with 2-cyano-5-fluorobenzyl bromide under the alkaline condition to obtain 2-[(6-chloro-3, 4-dihydro-3-methyl-2, 4-dioxo-1 (2H)-pyrimidinyl) methyl]-4-fluorobenzonitrile, then the solvent system reacts with (R)-3-Boc-aminopiperidine under the alkaline condition, and the protective group is dissociated by using acid to obtain trelagliptin, and salt forming reaction is carried out on trelagliptin and succinic acid (SM4) to finally obtain the trelagliptin succinate serving as a type 2 diabetes resistant medicine. By adopting a one-pot method, the method has the advantages that the raw material cost is low, the yield is high, the post-treatment operation of each step of chemical reaction in multi-step reaction is reduced, the production period is greatly shortened, few impurities are generated in the reaction, the product quality is high, the use amount of chemical reagents is relatively reduced, and the method is relatively green and environment-friendly, and is beneficial to industrial production.

Description

technical field [0001] The invention belongs to the technical field of medicine synthesis, and in particular relates to a new preparation process of troxagliptin succinate, a medicine for treating type 2 diabetes. Background technique [0002] Trexagliptin succinate controls blood sugar levels by selectively and persistently inhibiting DPP-4. It is an ultra-long-acting dipeptidyl peptidase IV (DPP-4) inhibitor. Trexagliptin is the first once-weekly oral hypoglycemic drug marketed in the world, while similar DPP-4 inhibitors on the market need to be taken orally once a day. Zafatek's drug advantages will undoubtedly provide a more convenient treatment option for diabetic patients , significantly improving patient convenience and compliance. [0003] Trexagliptin succinate tablets are developed and manufactured by Takeda Pharmaceuticals (Takeda), trade name Standard 100mg / tablet for the treatment of type 2 diabetes. This product was approved for marketing by the Japanese M...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07D401/04C07C55/10C07C51/41
CPCC07C51/412C07C55/10C07D401/04Y02P20/55
Inventor 陈胜
Owner 山东永丞制药有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products